Gilead is paying $3.15 billion upfront, $5 billion total, for Tubulis, a Munich-based ADC biotech whose lead drug just posted a 59% response rate in platinum-resistant ovarian cancer.
That’s Gilead’s third deal of 2026. The company agreed to pay $7.8 billion for Arcellx and $1.67 billion for Ouro Medicines earlier this year. CEO Daniel O’Day told the JPMorgan Healthcare Conference in January that Gilead was approaching dealmaking from a “position of strength.” That’s over $12 billion in upfront commitments since January.
Gilead already bought access to Tubulis in 2024 for $20 million plus $415 million in milestones — so they had 18 months of platform diligence before writing the big check. $435 million in sunk costs before the full buyout.
The asset they’re really buying is TUB-040, a NaPi2b-directed topoisomerase-I inhibitor ADC in phase 1b/2 for platinum-resistant ovarian cancer and non-small cell lung cancer. NaPi2b is a graveyard: Roche, Mersana, and Zymeworks have axed or paused NaPi2b-directed programs over the past decade, most because clinical readouts fell short. Tubulis claims its technology expands the therapeutic window, delivering efficacy without intolerable side effects. A 59% overall response rate in a notoriously treatment-resistant indication is the evidence. Gilead is betting that number holds in a pivotal trial.
Gilead knows this space. The $21 billion Immunomedics deal in 2020 gave them Trodelvy, now a commercial anchor in the ADC portfolio. Tubulis will run as a dedicated Munich-based research hub rather than getting folded into Gilead’s wider organization, a structure suggesting the acquirer wants to preserve whatever’s producing those clinical results.
Tubulis raised $401 million in a Series C last year. That round now looks like a bridge to an exit, not a standalone buildout.
Pivotal trial timing wasn’t disclosed.
— Diana Kowalski